X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (152) 152
male (122) 122
female (120) 120
index medicus (115) 115
middle aged (111) 111
gastroenterology & hepatology (98) 98
life sciences (85) 85
adult (81) 81
aged (62) 62
hepatitis c, chronic - drug therapy (57) 57
treatment outcome (53) 53
hepatitis c (50) 50
cirrhosis (45) 45
genotype (45) 45
hepatitis c virus (45) 45
drug therapy, combination (44) 44
hepacivirus - genetics (44) 44
antiviral agents - therapeutic use (43) 43
gastroenterology and hepatology (43) 43
ribavirin (40) 40
care and treatment (35) 35
hepatitis (35) 35
hepatitis c, chronic - virology (31) 31
liver cirrhosis (31) 31
antiviral agents - adverse effects (30) 30
ribavirin - therapeutic use (30) 30
therapy (30) 30
abridged index medicus (29) 29
cancer (29) 29
liver (29) 29
human health and pathology (28) 28
antiviral agents - administration & dosage (27) 27
hepatocellular carcinoma (27) 27
interferon-alpha - therapeutic use (27) 27
analysis (26) 26
antiviral agents (26) 26
health aspects (26) 26
[ sdv ] life sciences [q-bio] (25) 25
interferon (25) 25
polyethylene glycols - therapeutic use (25) 25
[sdv]life sciences [q-bio] (24) 24
genetic aspects (24) 24
patients (24) 24
ribavirin - adverse effects (24) 24
rna, viral - blood (24) 24
drug therapy (22) 22
hepacivirus - drug effects (22) 22
hepatitis c, chronic - complications (22) 22
infectious diseases (22) 22
liver cancer (22) 22
prospective studies (22) 22
ribavirin - administration & dosage (22) 22
risk factors (22) 22
telaprevir (22) 22
hépatology and gastroenterology (21) 21
liver cirrhosis - drug therapy (21) 21
management (21) 21
viral load (21) 21
fibrosis (20) 20
multivariate analysis (20) 20
proline - analogs & derivatives (20) 20
virus-infection (19) 19
boceprevir (18) 18
france (18) 18
liver cirrhosis - complications (18) 18
prognosis (18) 18
recombinant proteins - therapeutic use (18) 18
retrospective studies (18) 18
young adult (18) 18
chronic hepatitis-c (17) 17
infections (17) 17
liver cirrhosis - virology (17) 17
medicine, general & internal (17) 17
aged, 80 and over (16) 16
france - epidemiology (16) 16
infection (16) 16
research (16) 16
digestive system diseases (15) 15
double-blind method (15) 15
follow-up studies (15) 15
genotype & phenotype (15) 15
clinical trials (14) 14
diagnosis (14) 14
hepatology (14) 14
interferon-alpha - administration & dosage (14) 14
interferon-alpha - adverse effects (14) 14
prevalence (14) 14
sustained virological response (14) 14
virus diseases (14) 14
[ sdv.mhep.heg ] life sciences [q-bio]/human health and pathology/hépatology and gastroenterology (13) 13
combination (13) 13
efficacy (13) 13
liver neoplasms - therapy (13) 13
oligopeptides - therapeutic use (13) 13
protease inhibitors (13) 13
survival (13) 13
adolescent (12) 12
biological response modifiers (12) 12
carcinoma, hepatocellular - therapy (12) 12
epidemiology (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 11/2019, Volume 71, Issue 5, pp. 1051 - 1052
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 04/2019, Volume 70, Issue 1, pp. e203 - e204
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Life Sciences
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 3, pp. 881 - 889.e1
Background & Aims We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in... 
Gastroenterology and Hepatology | Clinical Trial | Liver Disease | C209 | VX-950 | VX-951 | THERAPY | HEPATITIS-C VIRUS | COMBINATION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Single-Blind Method | Hepatitis C, Chronic - metabolism | Interferon-alpha - pharmacology | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Drug Therapy, Combination | Polyethylene Glycols - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Recombinant Proteins - pharmacology | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Hepatitis C, Chronic - genetics | Oligopeptides - pharmacology | RNA, Viral - drug effects | Ribavirin - pharmacology | Evaluation | Complications and side effects | Care and treatment | RNA | Interferon | Genetic aspects | Hepatitis C | Hepatitis C virus | Consulting services | Ribavirin
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 18, pp. 1839 - 1850
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 152, Issue 1, pp. 142 - 156.e2
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Journal Article